All In Biotech

Drug Trial Radar · NCT07873645

Study of UBT37034 Injection

A Phase Ib Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Multiple Subcutaneous Administration of UBT37034 Injection in Overweight/Obesity Trial Participants

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Sponsor type
Industry
First posted
Oct 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of UBT37034 for injection in participants who have obesity or are overweight. The main purpose is to learn more about the safety, tolerability, drug concentration, drug action and immune response of repeated UBT37034 administration. This is a single-center, randomized, double-blind, placebo-controlled study with multiple ascending doses. A total of 40 participants will be enrolled in 4 different dose groups. Participants will receive UBT37034 or placebo in an 8:2 random ratio with dose titration. The study will last up to 24 weeks and includes screening, treatment and safety follow-up periods.

Conditions

  • Overweight , Obesity

Interventions

  • UBT37034Drug

    Administered SC

  • PlaceboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: Baseline to Week23
  2. Change from baseline in physical examinationsTime frame: Baseline to Week 23
  3. Change from baseline in body temperatureTime frame: Baseline to Week 23
  4. Change from baseline in pulse rateTime frame: Baseline to Week 23
  5. Change from baseline in blood pressureTime frame: Baseline to Week 23
  6. Change from baseline in ECG QTcF intervalTime frame: Baseline to Week 23
  7. Change from baseline in ECG RR intervalTime frame: Baseline to Week 23
  8. Change from baseline in ECG heart rateTime frame: Baseline to Week 23
  9. Change from baseline in PHQ-9 total scoreTime frame: Baseline to Week 23
  10. Change from baseline in C-SSRS scoreTime frame: Baseline to Week 23

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.